- » About TSWJ
- » Abstracting and Indexing
- » Aims and Scope
- » Article Processing Charges
- » Articles in Press
- » Author Guidelines
- » Bibliographic Information
- » Contact Information
- » Editorial Workflow
- » Free eTOC Alerts
- » Open Special Issues
- » Published Special Issues
- » Resources and Tools
- » Special Issue Guidelines
TheScientificWorldJOURNAL
Volume 11 (2011), Pages 742-748
doi:10.1100/tsw.2011.72
Methods to Predict and Lower the Risk of Prostate Cancer
Department of Urology, University of Texas Health Science Center, San Antonio, USA
Received 30 September 2010; Revised 21 February 2011; Accepted 1 March 2011
Academic Editor: Scott Eggener
Copyright © 2011 Barbara Ercole and Dipen J. Parekh.
ABSTRACT
Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5α-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.